Clinical Trial Update: Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers [Phase 1]

View source ↗

Summary

This is a Phase 1 clinical trial update evaluating the combination of APG-1252 (Pelcitoclax) and cobimetinib in recurrent and advanced ovarian and endometrial c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer
• Uterine Corpus Carcinoma

Drugs mentioned

• APG-1252 (Pelcitoclax) (Pelcitoclax)
• Cobimetinib (cobimetinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING